November 18, 2026
Health news, explained with evidence
LIVE

Pediatric Allergy Treatments Face Significant Insurance Hurdles, Study Finds

🧠 AI Analysis 2 min read 👁 3

New research indicates that insurance delays and denials frequently prevent children from accessing essential biologic medications for severe asthma and allergies.

Pediatric Allergy Treatments Face Significant Insurance Hurdles, Study Finds🧠AI Analysis

Photo: Medical Xpress

Key points

  • Insurance approval for pediatric biologics can take a month or longer.
  • A significant portion of prescriptions for severe allergies and asthma are denied by insurers.
  • The study analyzed 326 prescriptions for children with an average age of 11 between 2018 and 2026.

A new study presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting has revealed that administrative barriers are significantly hindering access to pediatric treatments. Researchers found that insurance companies often delay or outright reject coverage for biologic therapies, even when specialist physicians determine they are necessary for a child's health.

Biologics are a class of injectable medications that target specific parts of the immune system responsible for allergic diseases. These treatments are typically prescribed for children suffering from severe eczema, chronic hives, food allergies, or asthma that does not improve with standard therapies. However, obtaining these drugs requires a process known as prior authorization, where insurers must approve the prescription before covering the cost.

The investigation tracked 326 biologic prescriptions issued at a children's hospital between 2018 and 2026. The patients involved had an average age of 11 years. According to findings published in the Annals of Allergy Asthma & Immunology, the approval process can often stretch beyond a month, and many requests are ultimately denied by insurance providers.

Dr. Aarti Pandya, a co-author of the study and ACAAI member, noted that these delays occur after a medical professional has already decided on the best course of action. She emphasized that forcing families to wait weeks for medication can put children at risk of developing serious, avoidable health complications. The research team is calling for a more streamlined and rapid approval system to better serve pediatric patients.

What to know: This research was based on data from a single hospital system and may reflect specific regional insurance challenges. Always consult with a qualified medical professional to navigate treatment options and insurance requirements for chronic conditions.

Source Medical Xpress — medicalxpress.com/news/2026-11-delays-denials-kids-dont-allergy.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.